Cadila Healthcare informs about press release

13 Dec 2021 Evaluate

Cadila Healthcare has informed that it enclosed a copy of press release dated December 13, 2021 titled ‘Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1076.45 -12.00 (-1.10%)
22-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1540.30
Dr. Reddys Lab 5872.65
Cipla 1481.55
Zydus Lifesciences 1076.45
Lupin 1712.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.